Over the years, the Food and Drug Administration has issued complete response letters rejecting numerous pharmaceutical applications due to insufficient clinical trial efficacy data, manufacturing quality control deficiencies, or unacceptable safety profiles. Pharmaceutical companies frequently must conduct additional clinical trials, modify manufacturing processes, or refine safety labeling before attempting to secure eventual regulatory approval for these candidate medications.